A Phase III, Randomised, Multicenter Study, Double-Blind for the Immunogenicity and Consistency Evaluation of 3 Lots of GSK Biologicals' Haemophilus Influenzae Type b (Hib) Conjugate Vaccine and Single-Blind and Controlled for the Evaluation of Safety an

StatusFinished
Effective start/end date22/02/1015/01/13

Funding

  • GlaxoSmithKline: $81,860.08

Keywords

  • Biotechnology & Drug Development, Infectious Diseases